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Abstract 
Traumatic brain injury is a risk factor for subsequent neurodegenerative disease, including chronic 
traumatic encephalopathy, a tauopathy mostly associated with repetitive concussion and blast, but 
not well recognized as a consequence of severe traumatic brain injury.  Here we show that a single 
severe brain trauma is associated with the emergence of widespread hyperphosphorylated tau 
pathology in a proportion of humans surviving late after injury. In parallel experimental studies, 
in a model of severe traumatic brain injury in wild-type mice, we found progressive and 
widespread tau pathology, replicating the findings in humans. Brain homogenates from these mice, 
when inoculated into the hippocampus and overlying cerebral cortex of naive mice, induced 
widespread tau pathology, synaptic loss, and persistent memory deficits. These data provide 
evidence that experimental brain trauma induces a self-propagating tau pathology, which can be 
transmitted between mice, and call for future studies aimed at investigating the potential 
transmissibility of trauma associated tau pathology in humans. 
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Introduction 
Traumatic brain injury (TBI) is a recognized risk factor for delayed neurodegeneration and 
dementia, particularly chronic traumatic encephalopathy (CTE). The neuropathological picture 
that is emerging with late survival from TBI is of a complex of pathologies featuring abnormalities 
in tau, amyloid beta, neuronal loss, axonal degeneration, neuroinflammation and blood-brain 
barrier disruption (Johnson et al., 2012, 2013; Hay et al., 2016). Of particular note is the emergence 
of hyperphosphorylated forms of the microtubule-associated protein tau in a stereotypical pattern 
and distribution regarded as pathognomonic of CTE (McKee et al., 2016). Specifically, in its early 
stage, CTE is recognized through the demonstration of clusters of perivascular neurons and glia 
containing hyperphosphorylated tau (P-tau), typically with patchy distribution and concentrated 
towards the depths of cortical sulci (Geddes et al., 1999; McKee et al., 2014, 2016; Mez et al., 
2017). There is a suggestion of hierarchical progression of pathology from these initially focal and 
patchy cortical P-tau deposits to more widespread cortical, medial temporal and subcortical grey 
matter in late-stage disease (McKee et al., 2014). However, the mechanisms by which this initially 
localized cortical pathology progresses to more widespread and generalized disease are still not 
known. 
In Alzheimer’s disease (AD), tau pathology appears to progress along neural networks, suggesting 
transcellular spread of tau through neural connections (Goedert et al., 2016). In vivo studies have 
described the spreading of AD-related tau pathology from local sites to distant regions of the brain 
(Clavaguera et al., 2009, 2013; de Calignon et al., 2012; Ahmed et al., 2014; Guo et al., 2016), 
and it has been suggested that tau aggregates – or seeds – serve as the agent of this spread, 
transmitting the aggregated/hyperphosphorylated state from cell to cell in a prion-like fashion 
(Prusiner, 2012; Clavaguera et al., 2013; Iba et al., 2013, 2015; Woerman et al., 2016). Prions are 
proteinaceous infectious agents consisting of misfolded prion protein (PrPSc), which propagate by 
imposing their abnormal structures on host-encoded cellular prion protein (PrPC) (Prusiner, 1982). 
As PrPSc prions colonize the affected patient, they perturb the function of the nervous system, 
leading to motor and neurophysiological deficits, cognitive decline, and ultimately death (Chiesa, 
2015). Whether TBI generates misfolded or aggregated forms of tau protein that propagate by 
inducing misfolding of native tau in injured tissue and can be transmitted from one individual to 
another (tau prions), is not clear (Prusiner, 2012; Mudher et al., 2017). We hypothesized that late 
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P-tau deposition after severe TBI (sTBI) would show prion behaviour, and addressed this 
hypothesis in sequential steps. First, we set out to demonstrate and characterize the deposition of 
P-tau late after sTBI as distinct from P-tau deposition in ‘normal’ aged human controls. Second, 
we sought the emergence of self-propagating P-tau pathology in wild-type (WT) mice subjected 
to sTBI that replicated P-tau pathology observed in humans long after a single focal TBI. Finally, 
we went on to establish whether this TBI-induced tauopathy could be transmitted between mice 
and cause neurological deficits, satisfying the requirements for a bona fide tau prion.  
 
Materials and methods 
Study design. The aim of the study was to test whether a single severe focal TBI was able to 
induce a self-propagating tauopathy. First, we analyzed the deposition of P-tau late after single 
TBI in humans. Next, we characterized the temporal evolution of tau pathology in WT mice 
subjected to severe controlled cortical impact. Last, we tested whether authentic tau prions are 
generated after trauma by attempting the transmission of tauopathy to naive mice by intracerebral 
inoculation of brain homogenates from TBI mice. 
Male C57BL/6J mice (8 to 9 weeks of age) from Envigo were used in this study. The animals were 
housed four per cage at controlled temperature (22 ± 2°C) and relative humidity (60 ± 5%) with a 
12/12-hour light/dark cycle and free access to pelleted food and water.  
All animal experiments were designed in accordance with the ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) guidelines (Kilkenny et al., 2010), with a commitment to 
refinement, reduction, and replacement, minimizing the numbers of mice, while using biostatistics 
to optimize mouse numbers (as in our previously published peer-reviewed work using the mouse 
TBI model (Zanier et al., 2016) and prion inoculation in mice (Bouybayoune et al., 2015)). Thus, 
for statistical validity, we used 8 to 12 for the behavioural tests, and 3 to 8 for biochemical analysis 
and histology. The mice were assigned to the different experimental groups using randomization 
lists (www.randomizer.org). Inoculations, behavioural and histological assessments were done by 
researchers blinded to the experimental groups. 
Ethics statement. Human tissue was obtained from the Glasgow TBI Archive of the Department 
of Neuropathology, Queen Elizabeth University Hospital, Glasgow, UK. Tissue samples were 
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acquired at routine diagnostic autopsy, with approval from the Greater Glasgow and Clyde 
Biorepository Governance Committee for their use in research. Procedures involving animals and 
their care were conducted in conformity with the institutional guidelines at the IRCCS – Mario 
Negri Institute for Pharmacological Research in compliance with national (D.lgs 26/2014; 
Authorization n. 19/2008-A issued March 6, 2008 by Ministry of Health) and international laws 
and policies (EEC Council Directive 2010/63/UE; the NIH Guide for the Care and Use of 
Laboratory Animals, 2011 edition). They were reviewed and approved by the Mario Negri Institute 
Animal Care and Use Committee that includes ad hoc members for ethical issues, and by the Italian 
Ministry of Health (Decreto no. D/07/2013-B and 301/2017-PR). Animal facilities meet 
international standards and are regularly checked by a certified veterinarian who is responsible for 
health monitoring, animal welfare supervision, experimental protocols and review of procedures. 
Human studies. At the time of the original diagnostic autopsy, whole brains were immersion-
fixed in 10% formal saline for a minimum of three weeks, then the specimens were examined, 
sampled and processed to paraffin tissue blocks.  For this study, 15 patients surviving a year or 
more from single moderate or severe, closed TBI (defined as Glasgow Coma Scale at presentation 
< 13) and 15 age matched controls with no history of TBI or of known neurological disease were 
randomly selected from the comprehensive databases of the Glasgow TBI Archive by a laboratory 
research assistant with no knowledge of study purpose or design or of the pathologies in each of 
the TBI cases and controls selected. Full demographic information for late TBI cases and controls 
is contained in Supplementary Table 1. Information on TBI and controls history was obtained from 
review of diagnostic post-mortem and/or forensic reports. The TBI survival cases and the age-
matched controls, had no recorded history of exposure to contact sports or military service, nor 
abuse or other injuries. Mechanism of injury is summarized in Supplementary Table 1. None were 
penetrating. From review of the original hospital records, at presentation, intracerebral 
haemorrhage was present in 5 cases, subdural a further 7, with 3 cases having no evidence of 
intracranial haemorrhage.  Following the original TBI, all cases were discharged from 
hospitalization following recovery and, ultimately, died from causes of death unrelated to TBI. 
None were in a persistent vegetative state prior to death. Each case was sampled and assessed for 
this study as standardized regions, no matter the injury severity or location. As this study accesses 
archival tissue blocks, there were necessary restrictions on availability of sampled regions. 
Nevertheless, the standardized sampling protocols employed at the original diagnostic autopsy 
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included a coronal slice of the cerebral hemispheres at mid-thalamic level from which tissue blocks 
from multiple brain regions were selected for the purposes of this study to include: the corpus 
callosum with adjacent cingulate gyrus; the medial temporal lobe to include the hippocampus and 
entorhinal cortex; the insular cortex and the thalamus. From these tissue blocks 8 μm sections were 
prepared for immunohistochemistry procedures. After deparaffinization and rehydration, 
endogenous peroxidase was quenched by immerging sections in 3% aqueous H2O2 for 15 minutes. 
Then, heat-induced antigen retrieval was done using a microwave pressure cooker for 8 minutes 
in preheated 0.1 M Tris EDTA buffer (pH 8), followed by blocking in 50 mL of normal horse 
serum (Vector Labs, Burlingame, CA, USA) per 5 mL of Optimax buffer (BioGenex, San Ramon, 
CA, USA) for 30 minutes. The sections were then incubated in antibody to phosphorylated tau 
(PHF1; 1:1000; gift from P. Davies, Feinstein Institute for Medical Research, Manhasset, NY, 
USA) at 4°C for 20h prior to washing and application of biotinylated secondary antibody for 30 
minutes, followed by an avidin biotin complex, as per the manufacturer’s instructions (Vectastain 
Universal Elite Kit, Vector Labs, Burlingame, CA, USA). The target antigen was visualized using 
the DAB peroxidase substrate kit (Vector Labs, Burlingame, CA, USA), with the sections then 
counterstained with hematoxylin. Control sections (positive and negative) for each antibody were 
run in parallel with the test sections to confirm antibody specificity. Sections were viewed blind 
to whether they were TBI or control, using a Leica DMRB light microscope (Leica Microsystems, 
Wetzlar, Germany) and the extent and distribution of tau pathology was assessed and semi-
quantitatively scored as: Score 0, where no tau pathology was present; Score 1, PHF1 pathology 
comprising immunoreactive NFT and neurites of sparse to moderate density in the transentorhinal 
cortex with or without small numbers in the CA1 sector of the hippocampus; Score 2, PHF1-
immunoreactive NFT and neurites as described for Score 1 together with NFTs extending into the 
fusiform gyrus (lateral to entorhinal cortex) and sparse tangles in the cortex (cingulate/insular 
blocks);  Score 3, contained PHF1-immunoreactive NFT and neurites in more widespread sectors 
of the hippocampus and subiculum, with extensive  medial temporal, cingulate and insular cortical 
involvement. 
Mouse model of traumatic brain injury. The controlled cortical impact brain injury mouse 
model used in this study accurately replicates both the mechanical forces and the main secondary 
injury processes observed in severe TBI patients with brain contusion and is associated with 
clinically-relevant behavioural and histopathological outcomes (Smith et al., 1995; Pischiutta et 
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al., 2018). Mice were anesthetized by isoflurane inhalation (induction 3%; maintenance 1.5%) in 
an N2O/O2 (70%/30%) mixture and placed in a stereotaxic frame. Rectal temperature was 
maintained at 37°C. Mice were then subjected to craniectomy followed by induction of controlled 
cortical impact brain injury as previously described (Zanier et al., 2016). Briefly, the injury was 
induced using a 3-mm rigid impactor driven by a pneumatic piston rigidly mounted at an angle of 
20° from the vertical plane and applied to the exposed dura mater, between bregma and lambda, 
over the left parieto-temporal cortex (antero-posteriority: –2.5 mm, laterality: –2.5 mm), at an 
impactor velocity of 5 m/s and deformation depth 1 mm, resulting in a severe level of injury (Smith 
et al., 1995). The craniotomy was then covered with a cranioplasty and the scalp sutured. Sham 
mice received identical anesthesia and surgery without brain injury. 
Transmission Studies. Brain homogenates (10% w/v in PBS) from the ipsi and contralateral 
cerebral cortex (including all the cortical tissue above the rhinal fissure) of mice 12 months from 
TBI or sham injury were inoculated in the hippocampus (A/P, –2.5 mm from bregma; L, ±2.0 mm; 
D/V, –1.8 mm) and overlaying cerebral cortex (A/P, –2.5 mm from bregma; L, ±2.0 mm; D/V, –
0.8 mm). Inocula were from single brains. The TBI brain homogenates showing the highest 
amounts of P-tau by Western blot were chosen for inoculation. Mice were injected bilaterally (2.5 
L each, injection speed of 1.25 μL/min). 
Novel object recognition. Mice were tested in an open-square grey arena (40 x 40 cm), 30 cm 
high, with the floor divided into 25 squares by black lines. The following objects were used: a 
black plastic cylinder (4 x 5 cm), a glass vial with a white cap (3 x 6 cm) and a metal cube (3 x 5 
cm). The task started with a habituation trial during which mice were placed in the empty arena 
for 5 minutes and their movements were recorded as the number of line-crossings. The next day, 
mice were placed in the same arena containing two identical objects (familiarization phase). 
Exploration was recorded in a 10-minute trial by an investigator blinded to the experimental group. 
Sniffing, touching and stretching the head toward the object at a distance of no more than 2 cm 
were scored as object investigation. Twenty-four h later (test phase) mice were placed in the arena 
containing two objects: one identical to one of the objects presented during the familiarization 
phase (familiar object), and a new, different one (novel object), and the time spent exploring the 
two objects was recorded for 10 min. Memory was expressed as a discrimination index, i.e. the 
time spent exploring the novel object minus the time spent exploring the familiar one, divided by 
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the total time spent exploring both objects; the higher the discrimination index, the better the 
performance. 
Immunohistochemistry and immunofluorescence. Mice were euthanized by cervical 
dislocation, brains were removed and fixed in 10% formalin for 24h, dehydrated in graded ethanol 
solutions, cleared in xylene, and embedded in paraffin. Serial sections (5 μm thick) were cut onto 
glass slides and  boiled in citrate buffer (10 mM pH 6.0, Dako) for antigen retrieval, followed by 
incubation with the following anti-tau monoclonal antibodies: AT8 (phospho-tau Ser202/Thr205; 
Thermo Fisher; 1:1000), AT180 (phospho-tau Thr231; Thermo Fisher; 1:1000), PHF1 
(Ser396/Ser404; from P. Davies; 1:4000) and MC1 (aa 312-322; from P. Davies; 1:100). AT8 and 
AT180 immunostaining was visualized using the ARK kit (Dako). For secondary staining of MC1 
and PHF1, slices were incubated with biotinylated goat anti-mouse IgG1 in Superblock Solution 
(Pierce), followed by visualization with the TSA Biotin System (Perkin Elmer) and DAB 
(diaminobenzidine) Substrate Chromogen System (Dako). 
Slices were examined by an Olympus BX-61 Virtual Stage microscope, interfaced with VS-ASW-
FL software (Olympus Tokyo, Japan). For quantification of the AT8-positive staining in TBI mice 
regions of interest (ROI) were selected according to the Paxinos atlas (Paxinos and Franklin, 2004) 
in coronal (bregma -1.6 mm) and sagittal (lateral 1.5 mm) sections. In TBI mice the ipsilateral 
cortex was analysed over an area 1 mm deep from the edge of the contusion (Pischiutta et al., 
2018) and the contralateral from midline to the entorinal cortex. In the inoculated mice ROIs 
included whole cortex, hippocampus, thalamus and cerebellum. The same ROIs were selected in 
sham mice. Images were acquired using a 60X oil objective with pixel size 0.115 μm. Acquisition 
was done over 5 μm thick stacks, with step size 1 μm. The different focal planes were merged into 
a single stack by mean intensity projection to ensure consistent focus throughout the sample. 
Images were analysed using Fiji software (http://fiji.sc/Fiji).  
The digital separation of DAB staining from hematoxylin signal was done by color deconvolution 
(http://www.mecourse.com/landinig/software/cdeconv/cdeconv.html) and the DAB channel was 
used for quantification. To ensure consistency of the segmentation in the image processing, we 
subtracted the intensity background from the image calculated by averaging non-specific signal in 
identified region of interest. Specific signal after the image processing was computed as positive 
pixels/total pixels, and reported as the percentage stained area for statistical analysis. 
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For immunofluorescence, brain sections on glass slides were boiled in citrate buffer and incubated 
in blocking solution with the following primary antibodies: anti-drebrin  (Fitzgherald, 1:200) an 
actin-binding protein enriched in dendritic spines, (Sekino et al., 2017) and anti-vesicular 
glutamate transporter-1 (VGLUT-1, Synaptic System, 1:6000), for analysis of the presynaptic 
compartment (Senatore et al., 2012). Slices were then incubated with biotinylated secondary 
antibody (Vecstain, 1:500) and streptavidin 647 (Molecular Probes, 1:500), and examined by 
confocal microscopy (FV-500 Olympus) acquiring images in two different areas of CA1 field of 
the hippocampus using a 60X oil objective. Z-Stack images were acquired: 0.2 μm z-distance, 3 
μm thick confocal z-stacks (optical section depth 0.2 μm, 21 sections/z-stack) and 1024x1024 pixel 
resolution. Confocal Images were deconvoluted (CellP) and puncta were identiﬁed with Imaris 
software using the “quality” parameter (Heise et al., 2016). Only puncta stringently conforming 
with the quality parameter entered analysis. 
Biochemical analysis. Frozen brain tissue was homogenized in 10 volumes of PBS. 
Homogenates were aliquoted and stored at -80°C until use. Western blot analysis of total brain 
homogenates with monoclonal antibody AT8 was done on heat-stable protein fractions prepared 
according to Petry et al. (Petry et al., 2014) to avoid the interfering signal due to endogenous 
immunoglobulins. Proteins (50 µg) were separated on Nu-Page 4-12% gels (Thermo Scientific) 
and blotted onto nitrocellulose membranes (Hybond, GE Healthcare). After blocking with 5% dry 
milk for 1h at room temperature, membranes were incubated overnight at 4°C with anti-total Tau 
(1:10000, Dako) or AT8 (1:500, Thermo Scientific), then with HRP-conjugated secondary 
antibodies (Santa Cruz). Peroxidase activity was detected using an ECL (Iluminata Forte) kit 
(Millipore, Billerica, MA, USA) and visualized with a ChemiDoc imaging system (Bio-Rad). For 
RIPA insoluble preparation 100 µL of brain homogenate were incubated for 20 min on an orbital 
shaker with 1% RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 0.25% Na-
deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF and protease inhibitors). 
Brain extract was ultracentrifuged for 60 min at 100000 g at room temperature. The pellet was 
resuspended in 450 µL of RIPA buffer and ultracentrifuged at 100000 g for 30 min at room 
temperature. The supernatant was carefully removed and the pellet was resuspended in 100 µL of 
1X Laemmli sample buffer and proteins analyzed by Western blot. 
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For assay of protease resistance brain lysates prepared in 0.05% Triton X-100 in PBS were 
centrifuged at 300 g for 5 min. Proteins (20 µg) in the supernatants were digested with pronase (0-
10 µg/mL; Sigma) in a final volume of 20 µL for 1 h at 37°C, then resolved by Nu-Page 4-12% 
gels and analysed by Western blot with primary anti-tau antibody BR135 (1:1000, gift from M. 
Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK (Goedert et al., 1989)). 
Electron microscopy. Three controls and three TBI inoculated mice were deeply anesthetized 
and perfused through the ascending aorta with phosphate buffered saline (PBS, 0.1 M; pH 7.4) 
followed by a 5 minute perfusion with 4% paraformaldehyde. Hippocampus was excised and cut 
in sagittal plane with a razor blade and postfixed in 4% paraformaldehyde and 2% glutaraldehyde 
in phosphate buffer 0.12 M, then for 2h in OsO4. After dehydration in graded series of ethanol, 
tissue samples were cleared in propylene oxide, embedded in Epoxy medium (Epoxy Embedding 
Medium kit; Sigma-Aldrich) and polymerized at 60°C for 72h.  From each sample, one semithin 
(1 μm) section was cut with a Leica EM UC6 ultramicrotome and mounted on glass slides for light 
microscopic inspection to identify the stratum oriens of the hippocampus. Ultrathin (70 nm thick) 
sections of the areas of interest were obtained, counterstained with uranyl acetate and lead citrate, 
and examined with an Energy Filter Transmission Electron Microscope (Libra120, Carl Zeiss NTS 
GmbH) equipped with a yttrium aluminium garnet scintillator slow-scan charge-coupled device 
camera (Sharp eye, TRS, Moorenweis, Germany). A ROI including the postsynaptic density (PSD) 
was manually traced and its area and thickness measured by iTem software (Olympus Soft Imaging 
Solutions, Germany) of 263 synapses in control inoculated mice and 262 in TBI inoculated mice 
fitting the following two criteria: (1) presence of a cluster of presynaptic vesicles (at least 3 of 
them); (2) presence of a defined synaptic cleft.  
 
Statistical analysis. All graphs represent the mean ± SEM. GraphPad Prism 7 was used for 
statistical analyses. A categorical assessment score was used to assess human tau deposition. 
Results were dichotomized in either ‘low’ score (0-1) or ‘high’ score (2-3) and the Chi square test 
was used to assess differences between groups. Data in mice were analysed by one-way analysis 
of variance (ANOVA), followed by Tukey’s test to assess differences in case of three or more 
groups (behavioural tests and temporal changes of tau deposition) or by unpaired t test. P values < 
0.05 were considered to be statistically significant. 
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Results 
Late P-tau deposition is common in human survivors of a single moderate/severe TBI, 
and exceeds that seen in age-matched controls. 
Representative tissue sections from the brains of patients surviving a median of 5 years (range: 1-
18 years) following a single moderate or severe, closed TBI [n=15; age 19-89 (median 60) years], 
or control subjects with no history of TBI or known neurological disease [n=15; age 20-92 (median 
60) years] (Supplementary Table 1) were stained for P-tau using antibody PHF1. In TBI patients 
surviving a year or more, PHF1-immunreactive profiles appeared as neurofibrillary tangles and 
immunoreactive neurites (singly and in plaques), astrocytes and plaques within all cortical layers, 
although often with higher density in the superficial cortical layers (Fig. 1A). Elsewhere, where 
hippocampal profiles were present, all sectors appeared involved, CA2 less frequent than other 
sectors in this series. Six cases showed involvement of structures in the region of the thalamus as 
sparse immunoreactive thalamic or nigral neurons, occasional neurites and immunoreactive 
astrocytes. Although the proportions of patients with PHF1-immunoractive tau pathology were 
similar in controls and TBI (12 cases with pathology in each group), the extent and distribution of 
the pathologies were considerably greater in survivors of TBI than in non-injured controls (Fig. 
1B). Specifically, in controls, PHF1-immunoreactive NFTs and neurites were largely restricted to 
sparse profiles in the entorhinal cortex, with just four cases showing more extensive pathologies 
extending to the hippocampus and cortex. In contrast, in late survivors of TBI, 9 of 12 PHF1-
immunoreactive cases displayed higher stage tau pathology, with PHF1-immunoreactive profiles 
in moderate to high density across the medial temporal lobe, including the hippocampus, and 
extending to the cortex. Neuritic P-tau positive profiles were found in the neuropil, many with a 
truncated, granular appearance as illustrated in Fig 1A. In three of 12 TBI cases with P-tau 
pathology immunoreactive neuronal and glial profiles showed focal clustering around cortical 
vessels, in two of these at the depths of sulci (Fig. 1A); appearances consistent with the 
pathognomonic pathology of CTE described in the preliminary NIH diagnostic criteria (McKee et 
al., 2016). One further TBI case, an 87 year old male with a 5 year survival following a road traffic 
accident, showed clusters of P-tau immunoreactive subpial astrocytes in the medial temporal lobe, 
consistent with ageing related tau astrogliopathy (Kovacs et al., 2016). Both in late TBI cases and 
controls the extent of P-tau pathology appeared to increase with increasing age; the higher score 
pathology encountered more often with increasing age. Specifically, the 4 controls with higher tau 
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scores (2 or 3) were among the older aged (74 years or above) controls. Of note, while again 
typically older within the cohort, the 9 late TBI cases with higher tau scores ranged from a younger 
age (age 59 years upwards) than controls. No clear association between survival duration and 
extent of tau pathology could be ascertained in this small series (Supplementary Fig. 1).   In 
keeping with injury severity, evidence of healed contusion was near ubiquitous; present in all but 
1 case. There was no association between presence or nature of intracranial haemorrhage, 
including contusions, and tau pathology. 
Single severe TBI induces a progressive tau pathology that spreads from the site of 
injury to remote brain regions in WT mice.  
We tested whether single focal brain trauma triggered propagating tau pathology in WT mice. 
Two-month-old C57BL/6J mice were subjected to sTBI (16 mice) or to sham injury (14 mice). 
Eight TBI and seven sham were sacrificed at 3 months and used for immunohistochemistry (IHC; 
4 TBI and 4 sham) or biochemical analysis (4 TBI and 3 sham). One TBI mouse was found dead 
at about four months, and the brain was not collected due to prolonged post-mortem delay. The 
remaining mice were culled at 12 months and used for IHC (4 TBI and 5 sham) and for 
biochemistry (3 TBI and 2 sham).  
Phospho-tau immunopositivity, assessed by AT8, AT180 and PHF1 antibodies, was evident in two 
out of four mice at 3 months post TBI and restricted to the hemisphere ipsilateral to injury, with 
concentration to the regions adjacent to injury (Fig. 2A, compare panels i and ii, and Fig. 2B, and 
Supplementary Fig. 2). In contrast at 12 months, both ipsi- and contralateral P-tau pathologies 
were present, supporting progressive spreading of tau pathology from the injured hemisphere (Fig. 
2A, compare panels i and iii, and Fig. 2B, Fig. 2C, compare panels iv and vi, and Fig. 2D, and 
Supplementary Fig. 2). Western blot analysis found increased levels of total and AT8-reactive tau 
in 1 frozen TBI brain compared to sham-injured controls at 3 months and in 2 out of 3 TBI brains 
at 12 months (and example is shown in Supplementary Fig. 3). Thus, 3 out of 7 TBI mice (~40%) 
developed pathological tau at 3 months, and 6 out of 7 (~85%) at 12 months. 
P-tau was observed as neuronal cytoplasmic, neuritic and glial profiles throughout the cerebral 
cortex, hippocampus (CA1 and CA3 fields) and thalamus, with pathology also in the striatum and 
zona incerta (Fig. 3). In addition, a notable observation was numerous small to medium sized, 
rounded, ‘grain-like’ profiles, particularly within the neuropil (Fig. 3C). Occasionally there was 
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faint clustering of these granular immunoreactive profiles (Fig. 3G), with still other examples 
showing apparent localization along cortical vessels (Fig. 3H). Elsewhere, glial cytoplasmic P-tau 
immunoreactivity was present within white matter of the corpus callosum.   
Tau prions are generated in TBI mice, causing transmission of tau pathology, 
synaptic loss and behavioural deficits. 
The evidence that TBI induced a P-tau pathology that progressively spread throughout the brain 
suggested formation of a self-templating tau conformation. To test whether this could be 
horizontally transmitted like a prion, causing brain dysfunction, we intracerebrally inoculated 10% 
brain homogenates from TBI and sham-injured mice into naive C57BL/6J mice. Brain 
homogenates of contused and contralateral hemispheres (TBIipsi and TBIcontra, respectively) 
showing increased levels of total and AT8-positive tau by Western blot at 12 months post TBI 
(Supplementary Fig. 3) were inoculated bilaterally into the hippocampus and overlaying cerebral 
cortex of the recipient mice (Fig. 4A). The mice were examined in the novel object recognition 
(NOR) test 8 and 12 months post inoculation (m.p.i.). There was an overt memory deficit in the 
TBIipsi- but not in the TBIcontra-inoculated mice at 8 m.p.i. (Fig. 4B). At 12 m.p.i the memory deficit 
persisted in the TBIipsi- and was also detected in the TBIcontra-inoculated mice (Fig. 4C). No 
memory deficit was seen in mice inoculated with sham-injured brain tissue. 
This was confirmed in an independent experiment in which we tested the effect of the inoculation 
of TBI brain homogenate, obtained from the injured hemisphere 12 months post injury, on 
recognition memory in the inoculated animals at an earlier time (4 m.p.i). Memory was already 
significantly impaired at four months, and this was confirmed at 8 m.p.i. (Fig. 5B and C). 
Locomotor activity was similar in sham and TBI inoculated mice, indicating that the deficit in the 
NOR test was not due to motor abnormalities (Fig. 4D and E, and Fig. 5D and E). 
The memory deficit was associated with hippocampal synaptic pathology. Analysis of pre- and 
post-synaptic compartments by quantitative VGLUT-1 and drebrin immunofluorescence showed 
marked synaptic loss in the stratum oriens of the CA1 region at 12 m.p.i. (Fig. 6A and B). Electron 
microscopy examination showed a significant decrease in PSD thickness and area in hippocampal 
synapses in TBI inoculated mice (Fig. 6C) consistent with impaired synaptic efficacyAnalysis of 
P-tau deposition by antibody AT8 showed a significant difference between sham and TBI 
inoculated mice not only at the site of injection, but also widespread throughout the brain (Fig. 7). 
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Specifically, P-tau neurons, neurites and glia were identified in the cerebral cortex, hippocampus 
(CA1, CA3, and hilus of the dentate gyrus) and thalamus, with morphologies similar to those 
observed in mice exposed to TBI, including widespread ‘grain-like’ profiles (Fig. 8B-I). In the 
cerebellum, P-tau immunoreactive cytoplasmic and neuritic inclusions were noted in association 
with Purkinje cells and within the granule cell layer (Fig. 8J-K). Consistent with widespread tau 
pathology, there was an increase in the amount of aggregated tau in the thalamus of TBI-inoculated 
mice (Supplementary Fig. 4). The tau conformer that accumulated in the brains of TBI-inoculated 
mice was partially resistant to protease digestion, yielding a pronase-resistant fragment of ~10 kDa 
(Supplementary Fig. 4C), consistent with tau prion formation (Sanders et al., 2014; Kaufman et 
al., 2016). 
Discussion 
The present study found that a single moderate or severe TBI in humans resulted in widespread 
tau pathology with a notable pattern and distribution. Further, a single severe TBI induced 
persistent and evolving tau pathology in WT mice, with characteristics similar to late post TBI tau 
pathology in humans, which progressively spread from the site of injury to ipsi- and contralateral 
brain regions. This TBI generated tau pathology could be transmitted to WT recipient mice by 
intracerebral inoculation, inducing tau aggregation, memory deficits and synaptic alterations. 
These results indicate that tau prions are generated in TBI, providing a mechanistic explanation 
for how a biomechanical insult might trigger self-sustained neurodegeneration. 
In the past decade, there has been growing recognition that repetitive mild TBI might set in motion 
brain pathological processes that place exposed individuals at risk for neurodegenerative disorders 
in mid-to-late life, particularly CTE. While there is also evidence that tau pathology may be seen 
many years after a single severe TBI, most attention has focused on the association between 
repeated mild TBI and CTE, with the common impression tau pathology is uniquely associated 
with repetitive mild TBI which dictates a distinct neurodegenerative disease. 
Here we confirm that widespread CTE-like tau pathology is present in survivors of a year or more 
after just a single moderate to severe TBI in humans, and in mice exposed to sTBI surviving up to 
one year from injury. In our series of 15 patients who survived a year or more post TBI, we found 
12 positive for tau. The extent and distribution of staining was considerably greater than that seen 
in age-matched, non-TBI controls, with some variation between TBI subjects. This inter-individual 
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variability appeared to follow a stereotypic pattern of deposition, reminiscent of hierarchical P-tau 
deposition in other neurodegenerative diseases (Braak and Braak, 1995; Kovacs, 2015). These data 
provide one possible neuropathological substrate for the increased or accelerated incidence of 
neurodegenerative disease in patients who survive a single moderate or severe TBI. Although the 
extent and distribution of P-tau pathology was greater in late TBI survivors, it was not possible to 
establish a clear association between survival interval and extent of tau pathology. Further, our 
data in this limited human study show similar percentages of cases with tau pathology in TBI and 
control groups, making it hard to establish whether TBI accelerates a preexisting age-related 
tauopathy, or triggers de novo tau deposition.  
A better understanding of the biology that underlies this process calls for tractable experimental 
models. Previous investigations have shown that TBI accelerates genetically determined tau 
deposition in transgenic mice overexpressing mutant or WT human tau (Yoshiyama et al., 2005; 
Hien T. Tran et al., 2011; H. T. Tran et al., 2011; Ojo et al., 2016), and can lead to tauopathy in 
WT mice (Goldstein et al., 2012; Kondo et al., 2015; Meabon et al., 2016). A few studies reported 
formation of tau aggregates shortly after sTBI in rats (Hawkins et al., 2013; Gerson et al., 2016), 
with only one study showing persistent tau pathology in WT mice (Kondo et al., 2015). Our data 
not only confirm de novo tau deposition in WT animals after single TBI, but also document 
widespread tau immunopositivity at chronic stages, with a pattern echoing our observations in 
human TBI cases, including grain-like profiles in the neuropil and perivascular deposits. 
Interestingly we observed an increase in total tau after TBI. This could be due to increased tau 
expression or impaired tau clearance, perhaps because of TBI-induced alterations in proteostasis 
mechanisms, such as the glymphatic system (Iliff et al., 2014), and/or formation of an intrinsically 
protease resistant tau conformer. 
To establish a direct contribution of TBI induced tau pathology to late symptomatology in a clean 
setting, we performed inoculation studies in which there are no confounding factors inherent to 
the biomechanical injury. We found that inoculation of mouse TBI homogenates induced tau 
pathology with formation of partially protease resistant tau, memory deficits and synaptic 
alterations in WT recipient mice, providing evidence for generation of authentic tau prions. 
Previous studies showed that fibrillar forms of recombinant tau or tau aggregates from AD patients 
or other tauopathies can accelerate the genetically determined tau pathology in mutant tau cells 
and mice (Clavaguera et al., 2009; Sanders et al., 2014; Kaufman et al., 2016; Woerman et al., 
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2016). More recently, aggregated tau isolated from AD brains and other tauopathies was shown to 
induce tau pathology when inoculated intracerebrally in WT mice (Lasagna-Reeves et al., 2012; 
Guo et al., 2016; Narasimhan et al., 2017), supporting the generation of self-propagating tau in 
AD. However, to the best of our knowledge no long-lasting memory deficits or other signs of brain 
dysfunction were documented in these animals, leaving open the question of whether toxic tau 
prions are formed in these models. The observation that TBI-induced tauopathy can be transmitted 
between WT mice and cause persistent memory deficits satisfies the main requirement for a toxic 
bona fide prion. Oligomeric or fibrillar forms of tau have been identified in different taupathies 
that may have distinct toxic potency and seeding properties (Goedert and Spillantini, 2017). Future 
studies should aim at identifying the abnormal tau species responsible for propagation of tau 
pathology and synaptic toxicity. It will also be important to immunodeplete tau from the inocula 
to rule out that persistent inflammatory processes and/or other TBI-related signalling pathways 
(Makinde et al., 2017; Pischiutta et al., 2018) may contribute to triggering tau pathology in the 
inoculated mice.  
Host PrPC is required for PrPSc replication and pathogenic effect (Chiesa, 2015). It will be 
interesting to assess if the same holds true for tau by testing the amnestic effect of TBI-induced 
tau prions in tau knockout mice. Finally, the development of bioassays and/or biochemical 
methods for measuring tau prion titers as for PrPSc prions, will enable to define the time lag 
between the biomechanical insult and the formation of the tau conformers responsible for seeding 
the spread of pathology. This will not only be important for therapeutic approaches targeting tau 
propagation (Holmes and Diamond, 2014), but also to assess the possible formation of infectious 
tau in humans post TBI. The demonstration of tau prions in human TBI will urgently require 
studies to determine whether neurosurgical intervention in such patients should conform to well 
established precautions for transmission of prion disease, as suggested by the Centers for Disease 
Control (https://www.cdc.gov/prions/cjd/infection-control.html) and the World Health Organization 
(http://www.who.int/csr/resources/publications/bse/WHO_CDS_CSR_APH_2000_3/en/). 
Acknowledgments 
We are grateful to Peter Davies for providing the PHF1 and MC1 antibodies and to Michael 
Goedert for the BR135 antibody. We also acknowledge Stefano Fumagalli and Pietro Veglianese 
for advice on quantification of immunofluorescent staining. 
 17 
Funding 
This work was supported by the National Institutes of Health (NIH NS094003 and NS038104) 
(DHS, WS); by NHS Research Scotland Career- Researcher Fellowship (WS); and the 
Alzheimer’s Association (AARG-18-532633) (ERZ, RC); DKM was supported by a Senior 
Investigator award from the National Institute for Health Research (UK). 
  
 18 
 
Bibliography 
 
Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A novel in vivo model 
of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of 
spread is determined by connectivity, not proximity. Acta Neuropathol 2014; 127: 667–83. 
Bouybayoune I, Mantovani S, Del Gallo F, Bertani I, Restelli E, Comerio L, et al. Transgenic 
fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis 
and phenotypic expression of disease. PLoS Pathog 2015; 11: e1004796. 
Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol. 
Aging 1995; 16: 271–278. 
de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. 
Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 2012; 73: 685–97. 
Chiesa R. The elusive role of the prion protein and the mechanism of toxicity in prion disease. 
PLoS Pathog 2015; 11: e1004745. 
Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates 
from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. 2013; 110: 
9535–9540. 
Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission 
and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909–13. 
Geddes JF, Vowles GH, Nicoll JA, Révész T. Neuronal cytoskeletal changes are an early 
consequence of repetitive head injury. Acta Neuropathol. 1999; 98: 171–178. 
Gerson J, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, DeWitt DS, et al. Tau 
Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate 
Onset of Pathology in Htau Mice. J. Neurotrauma 2016; 33: 2034–2043. 
Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and 
alpha-synuclein in neurodegeneration [Internet]. Brain 2017; 140(2): 266-278. 
Goedert M, Spillantini MG. Propagation of Tau aggregates. Mol. Brain 2017; 10(1): 18. 
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human 
microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of 
Alzheimer’s disease. Neuron 1989; 3: 519–526. 
Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, et al. Chronic 
traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse 
model. Sci Transl Med 2012; 4: 134ra60. 
Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al. Unique pathological tau 
conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice. J. Exp. Med. 
2016; 213: 2635–2654. 
Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR, et 
al. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: 
 19 
possible link between traumatic brain injury and sporadic tauopathies. J. Biol. Chem. 2013; 288: 
17042–17050. 
Hay J, Johnson VE, Smith DH, Stewart W. Chronic Traumatic Encephalopathy: The 
Neuropathological Legacy of Traumatic Brain Injury. Annu. Rev. Pathol. 2016; 11: 21–45. 
Heise C, Schroeder JC, Schoen M, Halbedl S, Reim D, Woelfle S, et al. Selective Localization of 
Shanks to VGLUT1-Positive Excitatory Synapses in the Mouse Hippocampus. Front. Cell. 
Neurosci. 2016; 10: 106. 
Holmes BB, Diamond MI. Prion-like properties of Tau protein: the importance of extracellular 
Tau as a therapeutic target. J Biol Chem 2014; 289: 19855–61. 
Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM-Y. Synthetic Tau Fibrils 
Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer’s-
like Tauopathy. J. Neurosci. 2013; 33: 1024–1037. 
Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM-Y. Tau pathology spread in 
PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is 
determined by the LC’s afferent and efferent connections. Acta Neuropathol. 2015; 130: 349–
362. 
Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al. Impairment of 
Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury. J. 
Neurosci. 2014; 34: 16180–16193. 
Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and 
white matter degeneration persist for years after a single traumatic brain injury. Brain 2013; 136: 
28–42. 
Johnson VE, Stewart W, Smith DH. Widespread τ and amyloid-β pathology many years after a 
single traumatic brain injury in humans. Brain Pathol. 2012; 22: 142–149. 
Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, et al. 
Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional 
Vulnerability In Vivo. Neuron 2016; 92: 796–812. 
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research 
reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8: e1000412. 
Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, et al. Antibody against early 
driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 2015; 523: 431–
6. 
Kovacs GG. Invited review: Neuropathology of tauopathies: principles and practice. 
Neuropathol. Appl. Neurobiol. 2015; 41: 3–23. 
Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, et al. Aging-related tau 
astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016; 131: 87–
102. 
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, 
Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from 
endogenous tau. Sci Rep 2012; 2: 700. 
 20 
Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau 
pathology in vivo. PloS One 2012; 7: e31302. 
Makinde HM, Just TB, Cuda CM, Perlman H, Schwulst SJ. The Role of Microglia in the 
Etiology and Evolution of Chronic Traumatic Encephalopathy. Shock 2017; 48: 276–283. 
McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, et al. The first 
NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of 
chronic traumatic encephalopathy. Acta Neuropathol. 2016; 131: 75–86. 
McKee AC, Daneshvar DH, Alvarez VE, Stein TD. The neuropathology of sport. Acta 
Neuropathol. 2014; 127: 29–51. 
Meabon JS, Huber BR, Cross DJ, Richards TL, Minoshima S, Pagulayan KF, et al. Repetitive 
blast exposure in mice and combat veterans causes persistent cerebellar dysfunction. Sci. Transl. 
Med. 2016; 8: 321ra6. 
Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. 
Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American 
Football. JAMA 2017; 318: 360–370. 
Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, et al. What is the 
evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol. 
Commun. 2017; 5: 99. 
Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, et al. Pathological tau 
strains from human brains recapitulate the diversity of tauopathies in non-transgenic mouse 
brain. J. Neurosci. 2017; 37: 11406-11423. 
Ojo JO, Mouzon B, Algamal M, Leary P, Lynch C, Abdullah L, et al. Chronic Repetitive Mild 
Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and 
Increased T-Tau and Tau Oligomers. J Neuropathol Exp Neurol 2016; 75: 636–55. 
Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA, USA: 
Academic Press; 2004.  
Petry FR, Pelletier J, Bretteville A, Morin F, Calon F, Hébert SS, et al. Specificity of anti-tau 
antibodies when analyzing mice models of Alzheimer’s disease: problems and solutions. PloS 
One 2014; 9: e94251. 
Pischiutta F, Micotti E, Hay JR, Marongiu I, Sammali E, Tolomeo D, et al. Single severe 
traumatic brain injury produces progressive pathology with ongoing contralateral white matter 
damage one year after injury. Exp. Neurol. 2018; 300: 167–178. 
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136–44. 
Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 
2012; 336: 1511–1513. 
Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion 
strains propagate in cells and mice and define different tauopathies. Neuron 2014; 82: 1271–88. 
Sekino Y, Koganezawa N, Mizui T, Shirao T. Role of Drebrin in Synaptic Plasticity. In: Drebrin. 
Springer, Tokyo; 2017. p. 183–201. 
Senatore A, Colleoni S, Verderio C, Restelli E, Morini R, Condliffe SB, et al. Mutant PrP 
 21 
suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing 
membrane delivery of VGCC alpha(2)delta-1 subunit. Neuron 2012; 74: 300–13. 
Smith DH, Soares HD, Pierce JS, Perlman KG, Saatman KE, Meaney DF, et al. A model of 
parasagittal controlled cortical impact in the mouse: cognitive and histopathologic effects. J. 
Neurotrauma 1995; 12: 169–178. 
Tran H. T., LaFerla FM, Holtzman DM, Brody DL. Controlled cortical impact traumatic brain 
injury in 3xTg-AD mice causes acute intra-axonal amyloid-beta accumulation and independently 
accelerates the development of tau abnormalities. J Neurosci 2011; 31: 9513–25. 
Tran Hien T., Sanchez L, Esparza TJ, Brody DL. Distinct temporal and anatomical distributions 
of amyloid-β and tau abnormalities following controlled cortical impact in transgenic mice. PloS 
One 2011; 6: e25475. 
Woerman AL, Aoyagi A, Patel S, Kazmi SA, Lobach I, Grinberg LT, et al. Tau prions from 
Alzheimer’s disease and chronic traumatic encephalopathy patients propagate in cultured cells. 
Proc. Natl. Acad. Sci. 2016; 113: E8187–E8196. 
Yoshiyama Y, Uryu K, Higuchi M, Longhi L, Hoover R, Fujimoto S, et al. Enhanced 
neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive 
mild brain injury in a transgenic tauopathy mouse model. J Neurotrauma 2005; 22: 1134–41. 
Zanier ER, Marchesi F, Ortolano F, Perego C, Arabian M, Zoerle T, et al. Fractalkine Receptor 
Deficiency Is Associated with Early Protection but Late Worsening of Outcome following Brain 
Trauma in Mice. J. Neurotrauma 2016; 33: 1060–1072. 
 
  
 22 
Figure Legends  
Figure 1. Tau pathology in survivors of a single moderate or severe TBI. (A) Typically, controls showed 
sparse P-tau immunoreactive neurofibrillary tangles and neurites localized to the entorhinal cortex (i; 59-
year-old male). In contrast, patients surviving a year or more from single moderate or severe TBI showed 
more extensive neurofibrillary, neuritic and glial P-tau immunoreactive profiles, with occasional clusters 
around cortical vessels in a ‘CTE-like’ manner (ii; 59-year-old male 17 year survival from single severe 
TBI), and extending beyond the entorhinal cortex to involve wider grey matter regions including the 
hippocampus (iii; 87-year-old male 5 year survival from single severe TBI). (B) While the proportion of 
patients in TBI and controls with tau pathologies was similar, following TBI the extent and distribution of 
pathology was considerably greater. Thus, using a semi-quantitative scheme to score tau distribution, while 
all but 4 controls showed no or only localized tau pathology (Score 0 or 1), in a majority of TBI cases (9 of 
15) P-tau pathology was widespread (Score 2 or 3; p=0.0035; ChiSq). All sections stained for PHF-1. Scale 
bar: 100 m. 
Figure 2. Evidence of tau pathology in mouse TBI. AT8 immunostaining and quantification of the AT8-
positive area in the ipsilateral and contralateral cortex of sham and TBI mice at 3 and 12 months post injury. 
(A, B) AT8 immunoreactivity is detected in the ipsilateral (ipsi) pericontusional cortical area in 2 out of 4 
mice at 3 months post TBI, and in all mice at 12 months. (C, D) In the contralateral cortex AT8 
immunoreactivity is detected only after 12 months post TBI. Data are mean ± SEM; n = 4-5; *p < 0.05; **p 
< 0.01 by one-way ANOVA, Tukey post-hoc test. Scale bar: 100 m (B, D). 
Figure 3. Widespread tau pathology in mice 12 months post TBI. Examples of tau immunostaining with 
the AT180 (A, F), PHF1 (B), and AT8 (C-E, G, H) antibodies in the cerebral cortex (A, B), CA1 (C) and 
CA3 (D) fields of the hippocampus, and in the zona incerta (E, F). Examples of clusters of small to medium 
sized, rounded, ‘grain-like’ profiles, in the zona incerta (G), and granular profiles along a cortical vessel 
(H; arrows). Scale bars: 20 m (A-D, G); 10 m (E, F); 50 m (H). 
Figure 4. Inoculation of contused tissues induces memory deficits in wild-type mice. (A) Groups of 
mice used in the inoculation studies. C57BL/6J male mice were either left untreated (white) or inoculated 
bilaterally into the hippocampus and overlaying cerebral cortex with 10% brain homogenates from sham 
mice (grey) or from the contused (TBIipsi, indigo) or contralateral (TBIcontra, magenta) hemisphere at 12 
months post TBI. (B, C) Recognition memory was investigated by the novel object recognition (NOR) test 
at 8 (B) and 12 (C) months after inoculation. Performance in the NOR task was expressed as discrimination 
index (the higher the discrimination index the better the performance). (D, E) Locomotor activity was 
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similar in naïve, sham and TBI inoculated mice at 8 (D) and 12 (E) months after inoculation. Data are mean 
± SEM; *p < 0.05, vs. naive; #p < 0.05 vs. sham by one-way ANOVA, Tukey post-hoc test.  
Figure 5. Memory deficits are already detected at four months post-inoculation. (A) Scheme of the 
groups of mice used in the inoculation studies. C57BL/6J male mice were either left untreated (white) or 
inoculated bilaterally into the hippocampus and overlaying cerebral cortex with 10% brain homogenates 
from sham (grey) or TBI (contused hemisphere, indigo) mice 12 months post-injury. (B, C) Recognition 
memory was investigated by novel object recognition (NOR) test at 4 (B) and 8 (C) months after 
inoculation. Histograms indicate the discrimination index (the higher the discrimination index the better the 
performance). (D, E) Locomotor activity was similar in sham and TBI inoculated mice at 4 (D) and 8 (E) 
months after inoculation. Data are mean ± SEM, n = 11-14. ***p < 0.001, **p < 0.01 vs. naive; ##p < 0.01 
vs. sham; by one-way ANOVA, Tukey post-hoc test. 
Figure 6. Synaptic alterations in the hippocampus of TBI inoculated mice. (A, B) Representative 
images of immunofluorescence staining and quantitative analysis of presynaptic (VGLUT-1; A) and 
postsynaptic (drebrin; B) markers in the hippocampus of the inoculated mice at 12 months post inoculation. 
Data are mean ± SEM; n = 5-6; *p < 0.05; **p < 0.01 by unpaired t-test. Scale bar: 10 m. (C) 
Representative electron micrographs of stratum oriens synapses, and quantification of the thickness and 
area of the postsynaptic density (PSD) in sham and TBI inoculated mice. Data are mean ± SEM; n = 3. 
*p<0.05 by unpaired t-test. Scale bar: 100 nm. 
Figure 7. Evidence of tau pathology in mice inoculated with TBI homogenates. Quantification of the 
percent area covered by AT8 staining in the cortex (A-C), hippocampus (D-F), thalamus (G-I), and 
cerebellum (J-L). Data are mean ± SEM; n = 3-6; *p < 0.05; **p < 0.01 by unpaired t-test. Scale bars: 100 
m (D-I) and 200 m (K, L). 
Figure 8. Widespread tau pathology in mice inoculated with TBI homogenates. Representative 
micrographs of tau immunostaining in the brains of mice inoculated with sham (A) and TBI (B-K) 
homogenates. Examples of immunostaining with AT8 (A-C, F-H, K), PHF1 (D, I, J) and conformation-
dependent antibody MC1 (E) in the hippocampus (A, B, E, F), cerebral cortex (C, D), thalamus (G, H, I) 
and cerebellum (J, K). CA1 and CA3, fields of the hippocampus; LMol, stratum lacunosum molecolare; M, 
molecular layer; PC, Purkinje cell layer; G, granule cell layer. Scale bars: 200 m (A, B); 50 m (C); 20 
m (E, F, G, J, K); 10 m (D, H); 5 m (I). 
 
